文献速递中毒与环境急症消化、代谢与肾脏急症

可卡因或甲基苯丙胺尿检阳性者中芬太尼阳性率的变化

Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine.
PubMed 文献 · JAMA Netw Open · 2019-04-05
一句话结论2013至2018年美国尿检数据显示,可卡因阳性标本中非处方芬太尼阳性率从0.9%升至17.6%,甲基苯丙胺阳性者从0.9%升至7.9%。

该横断面研究分析了2013年1月1日至2018年9月30日美国多家医疗实践机构提交的100万份独特患者尿检标本,采用液相色谱-串联质谱检测可卡因代谢物、甲基苯丙胺、芬太尼和去甲芬太尼。可卡因阳性标本中非处方芬太尼阳性率从2013年的0.9%(n=84)显著升至2018年的17.6%(n=427),增幅1850%(τ=0.78;z=9.45;P<.001)。甲基苯丙胺阳性标本中非处方芬太尼阳性率从2013年的0.9%(n=29)显著升至2018年的7.9%(n=344),增幅798%(τ=0.72;z=8.75;P<.001)。作者认为,可能未接触过阿片类的兴奋剂使用者暴露于芬太尼时过量风险增高,临床医生需注意疑似药物过量或物质使用障碍患者可能已知或未知地暴露于多种物质,包括兴奋剂与阿片类的组合。

要点

  • 可卡因阳性尿检标本中非处方芬太尼阳性率从2013年0.9%(n=84)升至2018年17.6%(n=427),增幅1850%(P<.001)。
  • 甲基苯丙胺阳性尿检标本中非处方芬太尼阳性率从2013年0.9%(n=29)升至2018年7.9%(n=344),增幅798%(P<.001)。
  • 作者认为,可能未接触过阿片类的兴奋剂使用者暴露于芬太尼时过量风险增高。
  • 作者指出,临床医生需注意疑似药物过量或物质使用障碍患者可能已知或未知地暴露于多种物质,包括兴奋剂与阿片类的组合。
  • 该研究为横断面设计,标本来自美国多家医疗实践机构,排除报告处方芬太尼者的标本。

适用人群与场景

  • 2013年1月1日至2018年9月30日期间由医疗专业人员作为常规诊疗一部分提交尿检的美国患者标本,来自物质使用障碍治疗中心、疼痛管理实践、初级保健实践、行为健康实践、妇产科实践和多专科集团。
  • 排除报告被处方芬太尼者的标本。
  • 从Millennium Health尿检数据库随机选取100万份独特患者尿检标本(便利抽样方法),每份标本均有可卡因、甲基苯丙胺和芬太尼尿检结果。

研究设计与关键结果

  • 研究类型:横断面研究,分析100万份独特患者尿检标本(中位[四分位距]年龄44[19-69]岁;55.0%为女性)。
  • 检测方法:液相色谱-串联质谱检测苯甲酰芽子碱(可卡因代谢物)、甲基苯丙胺、芬太尼和去甲芬太尼。
  • 可卡因阳性标本中非处方芬太尼阳性率:2013年0.9%(n=84)(95%CI 0.7%-1.1%)vs 2018年17.6%(n=427)(95%CI 16.1%-19.1%),增幅1850%(τ=0.78;z=9.45;P<.001)。
  • 甲基苯丙胺阳性标本中非处方芬太尼阳性率:2013年0.9%(n=29)(95%CI 0.6%-1.2%)vs 2018年7.9%(n=344)(95%CI 7.1%-8.7%),增幅798%(τ=0.72;z=8.75;P<.001)。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,可能未接触过阿片类的兴奋剂使用者暴露于芬太尼时过量风险增高。
  • 作者指出,临床医生需注意疑似药物过量或物质使用障碍患者可能已知或未知地暴露于多种物质,包括兴奋剂与阿片类的组合。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Drug overdose deaths continue to increase, despite the leveling off of prescription opioid use and policy changes limiting opioid prescribing. Illicit fentanyl is the leading cause of drug overdose death, and it is important to characterize the emerging combination of other illicit drugs with fentanyl, which increases the risk of overdose.

OBJECTIVE: To determine whether rates of the combination of nonprescribed fentanyl with cocaine or methamphetamine have changed in urine drug test (UDT) results through time.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study of UDT results from January 1, 2013, through September 30, 2018, included patient specimens submitted for UDTs by health care professionals as part of routine care. Patients were selected from health care practices across the United States, including substance use disorder treatment centers, pain management practices, primary care practices, behavioral health practices, obstetrics and gynecology practices, and multispecialty groups. The UDT analysis used liquid chromatography-tandem mass spectrometry to detect benzoylecgonine (cocaine metabolite), methamphetamine, fentanyl, and norfentanyl. Specimens from individuals reported to have been prescribed fentanyl were excluded. A convenience sample approach was used to randomly select 1 million unique patient UDT specimens from Millennium Health's UDT database for further analysis. Each specimen had associated cocaine, methamphetamine, and fentanyl UDT results.

EXPOSURES: Medically necessary UDT to detect benzoylecgonine (cocaine metabolite), methamphetamine, fentanyl, and norfentanyl, ordered by a health care professional as part of routine patient care.

MAIN OUTCOMES AND MEASURES: Rates of nonprescribed fentanyl positivity among cocaine- or methamphetamine-positive UDT results, quantified through time.

RESULTS: In a sampling of 1 million unique patients' UDT specimens analyzed for cocaine and fentanyl (median [interquartile range] age, 44 [19-69] years; 55.0% women), positivity rates for nonprescribed fentanyl among the cocaine-positive results increased significantly, from 0.9% (n = 84) (95% CI, 0.7%-1.1%) in 2013 to 17.6% (n = 427) (95% CI, 16.1%-19.1%) in 2018, a 1850% increase (τ = 0.78; z = 9.45; P < .001). In the same sampling of 1 million specimens, positivity rates for nonprescribed fentanyl among the methamphetamine-positive results also increased significantly, from 0.9% (n = 29) (95% CI, 0.6%-1.2%) in 2013 to 7.9% (n = 344) (95% CI, 7.1%-8.7%) in 2018, a 798% increase (τ = 0.72; z = 8.75; P < .001).

CONCLUSIONS AND RELEVANCE: An increasing number of UDT results positive for cocaine or methamphetamine were also positive for nonprescribed fentanyl. This provides additional insight into recently reported increases in cocaine- and methamphetamine-related overdoses. Stimulant users who may be opioid naive are at a heightened risk of overdose when exposed to fentanyl. Clinicians need to be aware that patients presenting for treatment of suspected drug overdose or substance use disorder may have been exposed, knowingly or unknowingly, to multiple substances, including the combination of stimulants and opioids.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. LaRue L, Twillman RK, Dawson E, et al. Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine. JAMA Netw Open. 2019. PMID: 31026029. doi:10.1001/jamanetworkopen.2019.2851

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。